NEW HAVEN, Conn., Dec. 6, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product ...
DiaMedica Therapeutics (DMAC) is expected to complete enrollment for an interim futility analysis of its phase 2/3 ReMEDy2 clinical trial, using DM199 for the treatment of patients with acute ischemic ...
YONKERS, N.Y., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (CFRX) (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents ...
On Monday, Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and favezelimab. Vibostolimab is being evaluated as an investigational ...
UTRECHT, The Netherlands--(BUSINESS WIRE)--AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today provided a business update and the outcome from ...
(RTTNews) - Immunic, Inc. (IMUX) Tuesday announced positive outcome from the interim futility analysis of its Phase 3 ENSURE program evaluating the company's lead asset, IMU-838 for the treatment of ...
Two phase 3 trials evaluating a subcutaneous (SC) formulation of efgartigimod (efgartigimod alfa and hyaluronidase-qvfc [PH20]), a neonatal Fc receptor blocker, for the treatment of moderate to severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback